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Abstract 
Introduction: Localized trauma-derived breakdown of the hyaline articular cartilage may progress toward 
osteoarthritis, a degenerative condition characterized by total loss of articular cartilage and joint function. Tissue 
engineering technologies encompass several promising approaches with high therapeutic potential for the 
treatment of these focal defects. However, most of the research in tissue engineering is focused on potential 
materials and structural cues, while little attention is directed to the most appropriate source of cells endowing 
these materials. In this study, using human amniotic membrane (HAM) as scaffold, we defined a novel static in 
vitro model for cartilage repair. In combination with HAM, four different cell types, human chondrocytes, 
human bone marrow-derived mesenchymal stromal cells (hBMSCs), human amniotic epithelial cells, and human 
amniotic mesenchymal stromal cells (hAMSCs) were assessed determining their therapeutic potential. 
Material and Methods: A chondral lesion was drilled in human cartilage biopsies simulating a focal defect. A 
pellet of different cell types was implanted inside the lesion and covered with HAM. The biopsies were 
maintained for 8 weeks in culture. Chondrogenic differentiation in the defect was analyzed by histology and 
immunohistochemistry. 
Results: HAM scaffold showed good integration and adhesion to the native cartilage in all groups. Although all 
cell types showed the capacity of filling the focal defect, hBMSCs and hAMSCs demonstrated higher levels of 
new matrix synthesis. However, only the hAMSCs-containing group presented a significant cytoplasmic content 
of type II collagen when compared with chondrocytes. More collagen type I was identified in the new 
synthesized tissue of hBMSCs. In accordance, hBMSCs and hAMSCs showed better International Cartilage 
Research Society scoring although without statistical significance. 
Conclusion: HAM is a useful material for articular cartilage repair in vitro when used as scaffold. In 
combination with hAMSCs, HAM showed better potential for cartilage repair with similar reparation capacity 
than chondrocytes. 
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Introduction 
Decades of research in tissue engineering for effective treatment of articular cartilage have led to 
a variety of therapeutic approaches.
1,2
 However, to date, none of these approaches has been yet 
successful in overcoming the poor intrinsic repair response of articular cartilage. Articular cartilage is 
an avascular, aneural, and aliphatic tissue with particular low cell density.
3
 On the other hand, 
cartilage has high demanding functional requirements even at the time of treatment, which could 
determine reparation failure.
4





The development of engineered grafts for cartilage regeneration has tried the creation of a 
favorable microenvironment for native cells harbored on the cartilage and for new implanted cells. 
This strategy could assist in the function of implanted cells to restore lost tissue, avoiding the 
progressive degeneration of the articular cartilage to osteoarthritis (OA).
7
 However, one of the main 
problems in tissue engineering is the lack of integration with the surrounding native cartilage, 
resulting in the absence of long-term functional implants. To enhance integration, there are several 
strategies centered in the use of natural scaffolds.
8
 One of the most promising tissues, used for ages as 
natural scaffold, is the human amniotic membrane (HAM). HAM or amnion is an embryonic tissue 
created from the extra-embryonic ectoderm.
9
 Numerous intrinsic properties allow its use as a 
biomaterial. It has low immunogenicity, anti-inflammatory properties, and capacity to act as an 
antimicrobial agent. In addition, HAM secretes a variety of growth factors and presents an important 
therapeutic value reducing fibrotic healing.
10
 Besides, HAM has special characteristics that may 
permit articular cartilage regeneration. It shares components with the extracellular matrix (ECM) of 
articular cartilage, with the presence of glycosaminoglycans (GAG), different types of collagen, or 
fibronectin.
11
 From a materials point of view, HAM ECM is elastic, flexible, and resistant to the 
traction forces. Furthermore, it holds an economic advantage over other biological materials because 
of its availability and easy harvest.
12
 All these properties increase the interest of the amnion as a 
substrate for the transfer of both autologous and allogeneic cells.  
 
For tissue engineering purposes another important point is to define the most appropriate and 
effective cell source to treat specific diseases. Bone marrow mesenchymal stromal cells (BMSCs) are 
the most widely studied type of cells and considered the gold standard when other mesenchymal cell 
sources have been studied.
13
 Nevertheless, BMSCs have several disadvantages such as low cell yield 
during isolation, decrease differentiation capacity associated at the age of the donor, or morbidity 
derived from the harvest method.
14
 All these reasons boost the search for alternative cell sources.  
 
Apart from its scaffold properties, HAM is one of the extra-embryonic tissues with significant 
potential as source of stem cells.
15
 It is an embryonic-derived noncontroversial tissue, its size secures 
good yield of cells, and is obtained without invasive or expensive procedures.
16
 Two different 
populations of stromal cells could be harvested, human amniotic mesenchymal stromal cells 
(hAMSCs) and human amniotic epithelial cells (hAECs).
17
 Additionally, another important benefit is 
its immunological privileges. As a tissue related to the fetomaternal tolerance during pregnancy, it 





The objective of this study was to develop an in vitro model for focal repair of human articular 
cartilage using HAM as biomaterial assessing the therapeutic potential of different cell sources.  
  
Materials and Methods  
Harvest and preparation of HAMs  
This study was approved by the Ethics Committee for Clinical Research of Galicia (Spain). 
Human placentas (n = 30) from healthy donors were obtained from selected caesarean sections at the 
Hospital Materno-Infantil Teresa Herrera (A Coruña, Spain). All the donors gave written informed 
consent before tissue and cell collection. Under stringent sterile conditions, the harvested placentas 
were placed in 199 Medium (Thermo Fisher Scientific, Waltham, MA) with an antibiotic cocktail 
composed of the following: cotrimoxazol 50µg/mL (Soltrim®; Almirall-Prodesfarma S.A., 
Barcelona, Spain), vancomycin 50µg/mL (Vancomicina Hospira®; Laboratorio Hospira S.L., 
Madrid, Spain), amykacin 50µg/mL (Amikacina Normon®; Laboratorios Normon S.A., Madrid, 
Spain), and B amphotericin 5µg/mL (Fungizona®; Bristol-Myers Squibb, New York, NY) for 6 to 20 
h at 4ºC. The HAM was carefully separated from the chorion and washed three to five times with 
0.9% NaCl solution to remove blood cells.  
Cryopreservation and thawing of amnion for its use as scaffold  
TheHAMused as scaffold (n = 13)was placed on a supportive sterile nitrocellulose filter (Merk 
Millipore, Darmstadt, Germany) and cut into 6x6 cm patches in 20mL of 199 Medium (Thermo 
Fisher Scientific) without antibiotics but with a cryoprotectant, 10% dimethyl sulfoxide (DMSO; 
Sigma-Aldrich, St Louis, MO). Each patch ofHAMwas cryopreserved following a protocol of 
controlled freezing using CM 2000 (Carburos Meta ´licos, Barcelona, Spain). Freezing rates were -
1ºC/min to a temperature of -40ºC, -2ºC/min to -60ºC, and -5ºC/min to -150ºC. All HAMs were 
stored in the gas phase of liquid nitrogen at -150ºC. Thawing was carried out for 5 min at room 
temperature followed by 37ºC until thawing was complete. To reduce cell damage due to osmotic 
changes, the DMSO was removed by sequential washing and progressive dilution with 0.9% NaCl at 
4ºC.  
Isolation and culture of human amnion-derived cells  
The HAMs used as source of stromal cells (n = 17) were processed following the protocol of 
Soncini et al.
17
 Briefly, HAM was cut into ~2x2 cm
2
 pieces and transferred into an enzymatic 
digestion buffer containing 2.4 U/mL of dispase (Thermo Fisher Scientific) in phosphate-buffered 
saline (MP Biomedicals, Inc., Santa Ana, CA) and incubated at 37ºC for 7 min. The digested tissue 
was centrifuged and the supernatant was discarded. The tissue was then subjected to a second 
enzymatic digestion containing 0.75 mg/mL of type I clostridial collagenase (Thermo Fisher 
Scientific) and 20µg/mL of deoxyribonuclease I (Sigma-Aldrich) in RPMI 1640 (Lonza, Basel, 
Switzerland) culture medium for 3 h at 37ºC. Following this digestion the resulting cell suspension 
was filtered through a sterile 70µm filter (BD Biosciences, Franking Lakes, NJ). The collected cells 
were designated as hAMSCs. Nondigested amnion fragments were incubated with a solution 
containing 0.25% trypsin-EDTA (Sigma- Aldrich) at 37ºC for 2–3 min. The resulting cell suspension, 
containing hAECs, was centrifuged at 600 g for 10 min. The cells were recovered in Dulbecco’s 
modified Eagle medium (DMEM; Sigma-Aldrich Quimica) with 20% fetal bovine serum (FBS; 
Lonza) and 1% penicillin-streptomycin (P/S) (Thermo Fisher Scientific) and seeded into 162 cm
2
 
culture flasks (Corning, New York, NY). Nonadherent cells were removed after 48 h of culture. Both 
hAECs and hAMSCs cells were cultured in a humidified 5% CO2 atmosphere at 37ºC until 70% 
confluency was reached. The cells were expanded to obtain enough number of cells for further 
experiments.  
  
Harvest of human BMSCs  
Immediately after hip joint surgery for prosthetic replacement, femoral heads were obtained 
aseptically from five patients with OA(mean age 65 years, range 50–70 years) after signing informed 
consent. The human bone marrow-derived mesenchymal stromal cell (hBMSC) were obtained after 
repeated washing of the bone marrow with DMEM supplemented with 5% FBS and 1% P/S. Then, 
cells were centrifuged at 600 g for 8–10 min and seeded into 162 cm
2
 culture flasks in a humidified 
5% CO2 atmosphere at 37ºC. After 48 h of culture nonadherent cells were removed changing the 
medium two to three times a week.  
Harvest and isolation of human articular chondrocytes  
The Autopsy Service of the Hospital Universitario A Coruña supplied cartilage samples derived 
from patients who underwent leg amputations due to peripheral vascular disease, diabetes, or chronic 
vascular inflammation. The Orthopedics Surgery Department provided cartilage samples from 
patients with partial or total knee/hip replacement.  
 
Cartilage samples, from femoral heads or knees, comprised 25 donors (15 male and 10 female) 
with a mean age of 67 years (from 25 to 85 years). Cartilage biopsies were aseptically removed, 
sliced full thickness (excluding the mineralized cartilage and subchondral bone), and washed in 




The excised cartilage slivers were placed in a Petri dish, minced, and transferred to 50mL falcon 
tubes where chondrocytes were isolated by sequential enzymatic digestion. First, minced cartilage 
slivers were incubated in 10mL of basic medium, containing 0.25% Trypsin-EDTA (Sigma- Aldrich) 
for 10 min at 37ºC under agitation. The supernatant, without chondrocytes, was discarded and the 
trypsinized cartilage was subjected to a second digestion. Twenty milliliters of extraction medium, 
containing collagenase (2 mg/ mL; Sigma-Aldrich), were added. After an overnight incubation on a 
shaker at 37ºC, digested dilution was filtered with a 70µm cell strainer (Corning) transferred to a 
50mL falcon tube. Then, cells were subjected to a centrifugation for 10 min at 600 g, supernatant was 
removed and chondrocyte number determined using a hemocytometer. Cells were expanded in 
DMEM with 10% FBS and 1% P/S into 162 cm
2
 culture flasks. Cells were cultured in a humidified 
5% CO2 atmosphere at 37ºC until 80% confluence was reached.  
 
In vitro differentiation studies  
Adipogenesis and Osteogenesis of hBM-MSCs (n = 5), hAECs (n = 11) and hAMSCs (n = 11) 
were done between passages 2 to 4. The different cells were detached using 0.25% trypsin-EDTA 




 into an eight-well chamber slide (Thermo Fisher Scientific) 
in growth medium until confluence. Adipogenesis was induced maintaining the cells in Bullekit 
Adipogenic Differentiation Medium (Lonza) for 21 days following the manufacturer’s instructions. 
In the case of osteogenesis induction, cells were cultured for 21 days using hMSC Bullekit 
Osteogenic Differentiation Medium (Lonza). Culture mediums were changed every 2–3 days. 
 
Chondrogenesis was assessed by micropellet formation (hBM-MSCs [n = 5], hAECs [n = 11], 
and hAMSCs [n = 11]) as previously described by Yoo and Johnstone with some modifications.
20
 




) from passages 2 to 4 were detached using trypsin-EDTA and 
centrifuged at 600 g for 10 min. The resulting pellets were cultured in chondrogenic differentiation 
medium, DMEM containing 15% FBS, supplemented with 5 mg/mL ascorbic acid (AA), 1/1000 
monotioglycerol (Sigma), and 1% P/S during the first 48 h to promote the induction of 
chondrogenesis. After 48 h, the medium was replaced by DMEM with 15% knockout serum (Gibco), 
1% P/S and supplemented with 1µL/mL AA, 10µM dexamethasone, 6µL/mL Transferrin, 1 x 10
7
 M 
retinoic acid (all from Sigma), and 10ng/mL recombinant human transforming growth factor-β3 
(Prospec- Tany Technogene Ltd., Rehovot, Israel) for 21 days. Medium was changed every 2–3 days.  
  
For control samples, each differentiation assay with their respective control cultivating hBMSCs, 
hAECs, and hAMSCs were cultured inDMEMmedium, containing 20%FBS and1% P/S for 21 days. 
Both kind of samples, control and differentiated, were evaluated using the same histological and 
immunohistochemical analyses.  
 
Analysis of in vitro differentiation. For these analyses, all samples were fixed using 4% 
paraformaldehyde. To evaluate adipogenesis, the presence of cytoplasmic lipid droplets in the 
cultures was revealed directly on the eight-well chamber slides by Oil-red O stain (OR). The same 
was done for osteogenesis, but analyzing the presence of mineral deposits using Alizarin Red (AR) 
stain according to a standard protocol. Quantification of positive histological staining for AR and OR 
was performed using the analiSIS_ software (version D) (Olympus, Melville, NY).  
 
Micropellets from chondrogenic differentiation were embedded in paraffin to carry out 
histological and immunohistological evaluation for the presence of hyaline cartilage-characteristic 
molecules.  
 
Histological and immunohistological analyses. For histological evaluation, 4µm-thick 
paraffin sections were deparaffinized in xylol and rehydrated in a graded series of ethanol. Sections 
were stained with hematoxylin and eosin (HE), toluidine blue (TB), safranin O (SO), and Masson’s 
modified trichrome (MT). For immunohistochemical studies, sections were incubated with 
monoclonal antibodies to detect type I (COLI) (Abcam, Cambridge, UK), COLII (Merk Millipore) 
collagens and proliferating cell nuclear antigen (PCNA, Calbiochem; Merk Millipore). Sections were 




 detection kit 
(Dako, Santa Clara, CA) was also used. Samples were examined using an optical microscope and the 
COLI and COLII levels were quantified using a plugin developed for Fiji ImageJ (GNU, General 
Public Licence). The International Cartilage Research Society (ICRS) visual histological score
21
 was 
the quantitative system selected to grade the damage cartilage repair. With this scoring, more reliable 
data were obtained to evaluate objectively the harvested results.  
  
Development of in vitro model for articular cartilage repair  




FIG. 1. Schematic representation of the timeline and development of the in vitro model. (A) Chronogram of the main steps of 
the model. (B) Design of the implanted cells over the stromal layer of the amnion. (C) Assembly of all the components, 
membrane-laden and cell pellet with the different type of cells are implanted into the injured cartilage plug. (D) Life images of 
the components of the in vitro system and their assembly: (d1) CellCrown_ system; (d2) drilled human cartilage plugs; (d3) 
assembly of the system with the membrane covering the cartilage lesion; (d4) assembled plug in culture. 
Amnion as scaffold. The HAM used as scaffold (n = 16) was placed on CellCrownTM (Scaffdex, 
Finland) disposable inserts with the stromal side of the HAM exposed to seed the different type of 
cells on it. All the cell types, chondrocytes, hBM-MSCs, hAECs, or hAMSCs, were seeded in a 




 (Fig. 1B). It was maintained in culture until the total confluence of the 
cells on the stromal side (max for 3 weeks) with DMEM plus 10% FBS and 1% P/S (Fig. 1D, d1). 
 
Harvesting of cartilage biopsies. Cartilage samples were both OA (n = 12) and healthy (n = 2) 
subjects. Cartilage selected to develop the in vitro focal repair model was harvested in slicers. The 
samples included male and female equally with a mean age of 77 ± 9 years. Then, they were cut with 
a biopsy punch (Biopsy Punch Stiefel, España) into 6mm diameter discs. For the focal injury, a lesion 
of 2mm diameter with a dental drill was created in the superficial zone of each cartilage (Fig. 1D, 
d2).  
 
Assembling of the in vitro repair model. Each patch of HAM with the cells on it was 
dismantled from the Cell- Crown system. Just before putting the HAM over the cartilage biopsies, a 
pellet of 6 x 10
5
-same-type-cells that were on the HAM, were deposited inside the drilled defect. For 
it, each cell type was put under a 600 g centrifugation for 8 min. The formed pellet was broken with 
two short pulses in the shaker and placed in the cartilage lesion. Cartilage plugs with cells inside of 
the lesion were placed in a six-well plate and submitted a short centrifugation. This step allowed 
concentrating the cells on the deep part of the lesion. Then, HAM was placed over the superficial 
zone of the 6 mmcartilage biopsies in such a way that the stromal layer of the HAM, where the cells 
were grown, was in direct contact with the superficial surface of the cartilage (Fig. 1C, D, d3).   
In vitro models for articular cartilage repair were developed for chondrocytes (n = 6), hBMSCs (n 
= 5), hAECs (n = 5), and hAMSCs (n = 6). Cartilage biopsies with the focal defect covered with the 
amniotic membrane, but without the cellular pellet inside the lesion were used as controls. All 
cartilage biopsies, loaded with the pellets or unloaded (Supplementary Fig. S1; Supplementary Data 
are available online at www.liebertpub.com/tea), and covered with the HAM were placed in six-well 
culture plates (Costar
©
, Washington, DC) and cultured for 8 weeks (Fig. 1, d4). Two milliliters of 
DMEM culture medium supplemented with 10% FBS and 1% P/S (for chondrocytes) and 
chondrogenic medium (for the models with hBM-MSCs, hAECs, and hAMSCs) was placed in each 
well and replaced twice weekly. The culture plates were incubated in a 5% CO2 humidified 
atmosphere at 37ºC. All procedures were performed under stringent sterile conditions. After 8 weeks 
in culture, the in vitro cartilage repair model was retrieved from the culture plate, embedded in 
paraffin, and processed for histological and immunohistochemical analyses.  
Statistical analysis  
Statistical analyses for the repair percentage of the lesion area, ICRS scoring scale, and the 
quantification of COLI and COLII for the different models were performed using SPSS 16.0 software 
for Windows. All the data are represented as mean ± standard error. When normal distribution of the 
samples was confirmed, two-tailed Student’s t test was applied. When normal distribution was not 




As we previously published, hAMSCs and hAECs showed similar differentiation capacity into the 






FIG. 2. In vitro differentiation capacity of three progenitor cells tested in the model. (a–c) After 21 days in culture without 
differentiation factors the indicated progenitor cells did not show specific adipogenic or osteogenic staining. When exposed to 
specific differentiation factors, all kind of progenitor cells presented capacity to differentiate into adipocytes (d–f), osteoblast 
(g–i), and chondrocytes (j–r). OR, Oil-red O staining; AR, Alizarin Red staining; HE, hematoxylin and eosin staining; TB, 
toluidine blue staining; COL2, immunohistochemistry for type II collagen. Scale bar: (a, h–j, l, m) 200µm, (b–d, f, g, k, n–r) 
100µm, and (e) 50µm. 
  
To determine the best source of cells to regenerate articular cartilage, we developed an in vitro 
model of articular cartilage repair comparing the differences in cartilage regeneration of HAM loaded 
with different sources of cells (chondrocytes, hBMSCs, hAMSCs, and hAECs). Chondrocytes and 
hBMSCs were considered as gold standards.  
 
Initially, cells were expanded (Fig. 3) and then cultured over the stromal layer of the HAM. 
Masson’s trichrome staining was used to visualize the cells growing over the HAM (Fig. 4A, C, E, 
G). All cell types were grown mainly on monolayer over the amnion and were able to synthetize 
some ECM, especially chondrocytes (Fig. 4B). In these conditions, chondrocytes maintained their 
phenotype, verified by COLII immunohistochemistry (Fig. 4B), ruling out that the dedifferentiation 
process was taking place. Also hBMSCs, hAMSCs, and hAECs showed positive presence of COLII 




FIG. 3. Morphology of human chondrocytes, hBMSCs, hAMSCs, and hAECs during in vitro expansion. Scale bar: 200µm. 
hAEC, human amniotic epithelial cell; hAMSC, human amniotic mesenchymal stromal cell; hBMSC, human bone marrow-




FIG. 4. Representative images, of the different cell-types cultivated over the stromal layer of the amniotic membrane before 
plug assembly. (a, b) Chondrocytes. (c, d) hBMSCs. (e, f) hAMSCs. (g, h) hAECs. COLII, immunoshistochemistry for type II 
collagen; MT, Masson’s trichrome staining. Scale bar: 100µm. 
  
When cells reached confluence over the amnion, the amnion was implanted in vitro filling a focal 
defect performed in human-derived condral plugs. The model was maintained for 8 weeks and then 
subjected to histology and immunohistochemistry evaluation.  
Histological study  
Implanted chondrocytes synthesized ECM and were able to integrate with the native cartilage. In 
the newly synthesized tissue, the cells showed a rounded morphology (Fig. 5A, a). hBMSCs also 
synthetized high amounts of new tissue that appear more abundant than when chondrocytes were 
implanted (Fig. 5A, b), though the ECMsynthetized by hAMSCs was even superior (Fig. 5A, c). In 
addition, the appearance of the repair tissue in hAMSCs was hyaline and contained some cells with a 
rounded morphology. On the other hand, hAECs showed the lowest amount of synthesized ECM and 
presented a poor morphological appearance with high nuclear size and reduced cytoplasm. Due to the 
pyknotic appearance of these cells, the presence of PCNA was tested by immunohistochemistry 
(Supplementary Fig. S2). In all cases, the repaired tissue showed a high cellularity than the remaining 





FIG. 5. (A) Histological analysis of the repair tissue present in the defect (a–d). The presence of proteoglicans was visualized 
by toluidin blue staining (e–h) and safranin O staining (i–l). The integration capacity of the membrane with the superficial 
layer of the native cartilage was analyzed with Masson’s trichrome staining (m–p). Yellow dotted line indicates the edges of 
native cartilage and new synthesized tissue in the lesion (a–l) and the integration of the native cartilage with the amnion (m–p). 
Scale bar: (o) 50µm and (a–n, p) 100µm. (B) Histomorphometric quantification of the repaired area. (C) Scoring of the repair 
tissue using ICRS scale. HE, hematoxylin-eosin staning; ICRS, International Cartilage Research Society; SO, safranin O 
staining. Graphics expressed the mean ± standard error. 
The presence of proteoglycans was visualized by SO and TB staining. Chondrocytes and 
hAMSCs showed metachromasia for both stains when compared with hBMSCs. In defects treated 
with hAECs SO staining was not detected, while TB staining exhibited slight positivity (Fig. 5A, e–
l).  
  
When the cells were grown overHAM,HAMadapted itself to the irregular superficial layer of OA 
cartilage, even in OA cartilage and in areas of normal cartilage (Fig. 5, Integration). When 
chondrocytes were included as the cell population, HAM showed the best quality integration (Fig. 
5A, m). When HAM containing hBMSCs, hAMSCs, or hAECs were applied a reduction in the 
superficial imperfections in OA cartilage was also observed (Fig. 5A, n–p).  
 
The extension of repaired tissue was quantified in the defect using Image J (Fig. 5B). When 
chondrocytes were used, the repair tissue filled between 54% and 83% of the injured area. For 
hBMSCs, these values varied between 50% and 90%. For hAMSCs the injury filling varied between 
40% to completely full defect. Finally, for hAECs a variation between 30% and 90% of filled injuries 
was calculated.  
 
ICRS scoring was used to evaluate the general grade of reparation in the model with the different 
cell types (Fig. 5C). Chondrocytes, hBMSCs, hAMSCs, and hAECs did not show significant 
differences in the scoring with values of 9.5 ± 3.7, 12.8 ± 5.0, 12.5 ± 6.2, and 11.8 ± 6.0, respectively.  
Immunohistochemical analyses  
The presence of specific components of the ECM in the repaired tissue was visualized with 
specific immunostainings for COLII and COLI. Controls with healthy human skin and cartilage were 
used to optimize the immunohistochemistry techniques (Supplementary Fig. S3). Positive staining for 
COLII was only detected in the cytoplasm of the different cell types, but not in the newly synthetized 
ECM of any cell type (Fig. 6A). The quantification of the presence of COLII showed higher signal 
for hAMSCs when compared to other cells, this difference was statistically significant when 





FIG. 6. (A) Immunohistochemical analysis for the presence of type II collagen and type I collagen on the repair tissue. Yellow 
dotted line pointed the interface between native cartilage and the repaired area. Scale bar: 100µm. (B) Histomorphometric 
quantification for the presence of type II collagen in the repair tissue. (C) Histomorphometric quantification for the presence of 
type I collagen in the repair tissue. COLII, immunohistochemistry for type II collagen; COLI, immunohistochemistry for type I 
collagen. Graph bars represented the values as mean ± standard error. *p < 0.05 by two-tailed Student’s t test; **p < 0.01 by 
Mann–Whitney test. 
The presence of COLI in hBMSCs was significantly higher than with other type of cells, none of 
them showing negligible levels of COLI staining (Fig. 6C). Therefore, most of the cell types 
presented an acceptable relation of new synthesized tissue and fibrotic tissue.  
Discussion  
The use ofHAMas a source ofmesenchymal progenitors cells and a scaffold for tissue engineering 
has grown in interest in the last fewyears. Fromamaterials point of view,HAMis the eldest natural 
biomaterial.
23–26 
It has been applied in tissue engineering approaches in ophthalmology, dermatology, 
odontology, cardiology, and gynecology.
27–31
 In addition, HAM has been used in preclinical and 
clinical studies for the repair of corneal tissue, spinal cord injuries, cerebral stroke, and Parkinson’s 
disease.
32– 35
 All these studies have demonstrated little risk of infection and high versatility as 
biomaterial.  
 
Trying to understand the diverse potential of HAM, some studies have focused on the mechanism 
underlying these wide applications. One of the most important properties of HAM is the low 
immunogenicity, enabling maternal-fetal tolerance during pregnancy.
36
 The two types of cells 
isolated from this tissue, hAMSCs and hAECs, lack the human leukocyte antigens (HLA)-A, -B, -C 
from class I major histocompatibility complex, HLA-DR or -DQ immunological response 
molecules.
37,38
 On the other hand, it was demonstrated that epithelial amniotic cells express high 
amount of HLA-G, a protein related to immune tolerance, which activates the apoptosis of cytotoxic 
T cell through Fas ligand.
39
 Furthermore, this immune privilege could facilitate allogeneic 
transplantation, preventing the use of immune suppression therapy for patients after HAM 
implantation.  
 
Another valuable point is that HAM is a discarded tissue after delivery, with reduced ethical 
concerns to its harvest. Different methods of preservation have been developed that facilitate their 




First reports on HAM were centered in its use as carrier supporting cells growth. In this aspect, it 
has demonstrated to be not only a good scaffold for different cells, but also to contain properties that 




Wound protection and pain reduction are also qualities suggested for HAM. HAM-derived cells, 
hAECs and hAMSCs, showed synthesis of anti-inflammatory factors, as tissue inhibitor 
ofmetalloproteases (TIMP)-1, TIMP-2, TIMP- 3, TIMP-4, and IL-10; a variety of growth factors, 
EGF, bFGF, or TGF-β1, TGF-β2, and TGF–β3; and antimicrobial substances/ agents, like β-defensin 
or secretory leukocyte protease inhibitor.
16,45,46
 In addition, on the stromal side of the HAM there is a 
suppression of the profibrotic TGF-β1 signaling system minimizing the scar tissue and promoting the 
reconstruction of the native tissue.
47
 Also, HAM is a biodegradable and permeable avascular 
structure. All these benefits have supported the easy translation for clinical purposes.     
 
There are some specific properties on the HAM that reinforced the idea of its use in cartilage 
regeneration; the simple but solid structure of HAM showed enough strength to overcome the high 
demanding mechanical environment on the joint.
48–51
 Furthermore,HAMshares numerous 
components of its matrix with the ECM of native articular cartilage as GAG, different types of 
collagen, or fibronectin.
11
 The natural synthesis of TGF-β1, -β2, and -β3 would facilitate the 
chondrogenic differentiation of MSCs without exogenous addition of differentiation factors favoring 




The stratification of the HAM might facilitate integration with the native cartilage seen in our 
results. Also, the plasticity and easy handling of the HAM would allow perfect fit into the inherent 
cracks and fissures present at the OA cartilage. This integration could potentially delay the evolution 





Lastly, despite the promising clinical results with autologous chondrocyte implantation, there are 
some limitations associated to the use of a periosteal flap. As detachment of the flap, delamination 
and hypertrophy, generated by the cells and factors of the periosteum, has been described.
53
 The 
replacement of the periosteal flap by HAM would prevent these limitations.  
 
Our group has demonstrated the utility of HAM as a source of mesenchymal progenitors cells for 
a variety of cell-based therapies.
54
 Here, the central idea of this report is to evaluate the specific 
application of HAM for cartilage regeneration. Even when this is not the first approximation to 
evaluate the superficial reparation of osteoarthritic cartilage with HAM as scaffold,
55
 it is the first 
study analyzing hAECs and hAMSCs for cartilage repair. But, in our view, the strength of this study 
is the comparison of HAM-derived progenitor cells with the two principal type of cells, hBMSCs and 
chondrocytes, used extensively in the clinic for cartilage repair. Between the benefits of HAM as 





We detected that all type of cells assessed exhibited good integration and adhesion with the native 
cartilage. Thus, the immobilization of the cell pellet inside the lesion contributed to fill the injured 
cartilage. Chondrocytes, hBMSCs, hAECs, and hAMSCs infiltrated the superficial zone (closer to the 
damaged area) and the edges of the lesion, decreasing the small fissures or irregularities characteristic 
of OA cartilage. Also, it was possible to detect a thickening of the stromal part of the HAM when 
implanted with chondrocytes, which could be derived of the growth and infiltration of cells that 
synthesize ECM, as reported when a chondrocytes implantation model is used.
57
      
Of note, there were no significant differences between the cells used in the clinic and the HAM-
derived cells. However, a deeper analysis through the presence of chondrogenic markers showed that 
hBMSCs presented a reduced level in the synthesis of COLII when compared with hAMSCs. 
Progenitor cells isolated from extra-embryonic tissues, as the amnion, have emerged as a potential 
alternative sharing properties of embryonic stromal cells and adult stem cells.
15
 There is the 
assumption that hAMSCs remain in a previous differentiation step than hBMSCs, thus, retaining a 
higher differentiation potential. Moreover, the repaired tissue by hBMSCs displayed the highest 
COLI content, an important marker of fibrotic tissue, confirming that the stimulus with chondrogenic 
factors was not enough for these cells. In this regard, the age of the donors is an important factor, and 
BMSCs were harvested from patients with a mean age of 65 years. Taking into account chondrocytes, 
even this source of cells does not seem the most appropriate, especially when lower levels of COLII 
were detected when comparing with the rest of nondifferentiated cells. These low competence of 
chondrocytes could be explained by ex vivo chondrocyte expansion, where chondrocytes lose their 
phenotype
58
 or because of the pathology background of chondrocytes.  
 
Overall, HAM is an optimal source of progenitor cells for cartilage repair purposes; progenitors 
cells could be obtained with high yields, without invasive and/or expensive procedures, being a 
noncontroversial source of stromal cells.
59
  
Limitations of the study  
This is an in vitro reparation model with important limitations. The main limitation is the lack of 
mechanical stimulus with recognized influence on the biochemical constitution and biosynthesis of 
cartilage molecules.
3
 The absence of these forces could explain the high content of COLII in the 
cellular cytoplasm not being delivered to the matrix. In addition to this, the cartilage used for these 
experiments was mainly derived from patients affected by OA, thus, the predominance of catabolic 
processes in OA cartilage may hamper some reparative properties of the assessed cells.
60,61
 Finally, as 
an in vitro model, important biochemical signals derived from the proximal cartilage tissues, synovial 




In this study we explored the use of HAM in the regeneration of articular cartilage, not only as 
scaffold but also as a source of progenitor cells. HAM demonstrated good capacity adhering to the 
superficial zone of the native cartilage as well as integrating into the surface structure. Furthermore, 
HAM-derived hAMSCs showed better reparation scores even when compared with BMSCs and 
chondrocytes, cells widely used in preclinical and clinical procedures.  
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